Robert Davidson is CURE’s CEO and creator of the technology. Prior to his role at CURE, he was President and CEO of InnoZen Inc., CEO of Gel Tech LLC and CEO of Bio Delivery Technologies Inc. Mr. Davidson also led the development of several drug delivery technologies and commercial brand extensions including Chloraseptic™, Suppress™, as well as Pediastrip™, and is the developer and holder of over 40 drug delivery patents. He holds a B.S. degree in Biological Life Sciences, a Master’s in Public Health, a Masters in Wellness, as well as a Master’s and Post Graduate Qualification at the University of Cambridge. Additionally, he holds a PhD in Public Health at UCN European Programs, DHAc Oklahoma State University, and Post Graduate Studies in Nanotechnology at the University of Oxford.